ArticleFrontiers in oncology2026
Habitat radiomics based on CT for assessing BRCA mutation status in patients with high-grade serous ovarian cancer: a multicenter study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to evaluate the potential of CT-based habitat radiomics in predicting BRCA mutation status in patients with high-grade serous ovarian cancer (HGSOC). The goal is to identify radiomic features from distinct tumor habitats that correlate with BRCA mutations and assess the predictive accuracy of various machine learning models. Methods: A total of 228 patients with histologically confirmed HGSOC were included in this multicenter, retrospective study, with 168 patients in the training cohort and 60 patients in the test cohort. Radiomic features were extracted from the entire tumor and subdivided into five distinct "habitats" based on local tumor features. Predictive models were developed for each of the following: clinical model, radiomics model (based on whole tumor characteristics), five habitat models (habitat1, habitat2, habitat3, habitat4, habitat5), and a combined habitat model (integrating habitat1-5). Five machine learning algorithms (logistic regression (LR), support vector machine (SVM), light gradient boosting machine (LightGBM), extreme gradient boosting (XGBoost)) were applied to each model. The model with the highest average area under the curve (AUC) across the algorithms in the training cohort was selected as the optimal model. Further comparison and evaluation of the optimal models from different algorithms were performed to determine the most reliable one. Results: Among the five machine learning algorithms, XGBoost showed the highest AUC in the training cohort but exhibited a significant drop in the test cohort, indicating overfitting. In contrast, the SVM model demonstrated more consistent performance across both cohorts, with an AUC of 0.952 in the training cohort and 0.841 in the test cohort, making it the most stable performer among the tested algorithms for predicting BRCA mutation status. Calibration and net benefit analyses further confirmed the potential of the SVM-based habitat model as a non-invasive exploratory tool. Conclusion: CT-based habitat radiomics offers a promising, non-invasive method for predicting BRCA mutation status in HGSOC. The combined habitat model outperformed traditional clinical and whole-tumor radiomic models by more effectively capturing tumor heterogeneity. SVM, demonstrating stable and reliable performance across datasets, emerged as the most robust model for clinical use. These findings support the integration of habitat radiomics, particularly SVM, for personalized, non-invasive molecular assessment in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.